Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


CapMan, Investor Growth Capital & Nobel Biocare are selling Swedish Entific to Australian Cochlear


04 Mar 2005 -- Entific was created in 1999 as a spin-off from the Swedish dental implant company Nobel Biocare and is today an international MedTech company that develops and markets hearing implants for rehabilitation of conductive and mixed hearing losses as well as Single Sided Deafness (SSD). Sales in 2004 reached EUR 23.4 million (SEK 211.5 million) and the pre-tax earnings were EUR 4.1 million (SEK 37 million).

Cochlear is a leading Australian MedTech company and develops and markets cochlear implants system for the treatment of profound deafness. Cochlear’s net sales totalled AUD 285.8 million (EUR 170.2 million or SEK 1,540) in 2004. The company is listed on the Australian Stock Exchange.

”We are very pleased with Entific’s development during our five-year investment period,” states Senior Partner Jan Lundahl, Head of CapMan Life Science. ”Today Entific is a globally successful company that has grown rapidly and profitably. With Cochlear as the new owner, the company will be an even stronger industrial player with exceptionally good preconditions to continue successful business development. We believe that the sale of Entific to an esteemed trade buyer such as Cochlear is an excellent outcome for both the company and its personnel.”

”The deal represents a perfect match and will give Entific a new larger platform to work from. It is a good solution for all the parties involved. Entific and Cochlear are complementary both from a company culture and product development point of view, but even more so as regards sales and marketing. The products of Entific and Cochlear target the same customer base and are sold to the same clinics and surgeons”, says Mr. Per Carendi, Chairman of the Board of Entific.

During the five years that Entific has been owned by CapMan’s Swedestart II Fund, Investor Growth Capita and Nobel Biocare, Entific has developed into a well established company with currently over 25,000 patients treated with the Baha® hearing implant. The bone anchored hearing implant, made of titanium, gives a unique possibility for ENT- and neurosurgeons throughout the world to treat Single Sided Deaf patients or patients with a conductive hearing loss who will regain a functioning hearing and hence be able to live a normal life. The treatment involves fairly non-invasive surgery. Under the leadership of Dan Pitulia, CEO, the turnover has increased six-fold since 1999 attributable to the establishment of an international sales and marketing organization in combination with a high pace of new product launches. The FDA clearance for Baha as a treatment option for Single Sided Deafness late 2002 has since been a major driving force for growth. The US has now become the most important market for Entific.

”Entific is a success story. The company has developed into a fantastic MedTech company with an average sales growth rate of 36% per annum, positive cash flow and good profitability. From a position as a non-core business unit within Nobel Biocare, Entific is today an international company with a strong foothold in a very attractive growth area with sales and marketing in the USA and the major European markets,” says Per Carendi.
Swedestart II Fund, which is managed/advised by CapMan, invested in Entific in 1999 and the increase in value of the investment is 6.3 times money back. Prior to the deal the fund held a 26.6% stake in the company. The exit does not effect on CapMan Plc’s result for 2005 nor does it have any substantial effect on the Group’s result in coming years.

The trade sale of Entific to Cochlear is the latest in a round of good news by CapMan Life Science investment operations. The sale of Swedish NeoPharma AB to Solvay Pharmaceuticals S.A. was finalised in January 2005. NeoPharma has developed the DuoDopa drug delivery system for the treatment of advanced Parkinson’s disease. In December 2004 the Finnish company Inion Oy completed a successful IPO on the Main List of the London Stock Exchan


Publisher Contact Information:

CapMan Capital Management Oy
+ 46 (0)8 545 85 475
-

Company profile of CapMan Capital Management Oy
Past press releases of CapMan Capital Management Oy.

Data


26,230
Tech investments
From our Online Data Service
16,944
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.